Tenderwize
Zurück zur Suche

Non-exclusive rebate agreement for Eltrombopag

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 35 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Eltrombopag (ATC-Code nach WHO: B02BX05)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Demand is explicitly unknown and depends on patient numbers, prescribing behaviour, and pharmacy stocking behaviour; mi...

Participation documents must be obtained through the DTVP project room, and the notice says submission cannot be made v...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive supply of pharmaceutical products containing Eltrombopag.
  • Conclusion of rebate agreements under § 130a Abs. 8 SGB V in an open-house model.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Eltrombopag (ATC B02BX05) led by AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No individual negotiations or exclusivity apply, and the purchase volume is unknown and not guaranteed. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis.

Risiken

Demand is explicitly unknown and depends on patient numbers, prescribing behaviour, and pharmacy stocking behaviour; mi...

Participation documents must be obtained through the DTVP project room, and the notice says submission cannot be made v...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • For the offered medicinal product, the company must have its seat in Germany, another EU Member State, or another EEA state, as stated in the notice.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds is required.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Non-exclusive rebate agreement for Eltrombopag

Supply lot for a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V for the active substance Eltrombopag (ATC B02BX05). The scope excludes the indication acquired severe aplastic anemia unless the bidder holds valid patent rights or a patent-preserving licence. Open-house model means any eligible pharmaceutical company may join during the participation period; no exclusivity or individual negotiation applies. Place of performance is Dresden, Germany, with performance geography also stated as Saxony and Thuringia in the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Sep 2025 - Sep 2026

Kategorie

Pharmaceutical products

Frist

Deadline Sep 30, 2026

Vergabedetails

Veröffentlichungsdatum
12 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
529414-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3